Clinical Research
corporate_fare

Aurinia Pharmaceuticals Inc.

Address
140-14315 118 Avenue Northwest

Sponsor Overview

assignment
1
sponsored trial
science
2
molecules
location_city
10
research centres
public
1
country
person_search
9
investigators

Specializations

Neuromuscular Disorders

Aurinia Pharmaceuticals Inc. is involved in clinical research focused on generalized myasthenia gravis, a chronic autoimmune neuromuscular disease that affects muscle strength and nerve-to-muscle communication.

  • Generalized Myasthenia Gravis
  • Neuromuscular junction dysfunction
  • Muscle weakness

The sponsor’s research interest in this area reflects attention to conditions requiring targeted immune modulation within neurology and autoimmune disease care.

Autoimmune Therapeutics

The funded research centers on immune-mediated disease mechanisms, with particular focus on pathways relevant to BAFF and APRIL biology in autoimmune regulation.

  • BAFF/APRIL pathway
  • Immune system modulation
  • Autoantibody-associated disease

This therapeutic domain aligns with efforts to address diseases driven by abnormal B-cell activity and persistent immune activation.

Immunology

Aurinia’s clinical research activity includes investigation of treatments aimed at altering immune signaling in patients with chronic inflammatory and antibody-mediated conditions.

  • B-cell mediated immunity
  • Immune signaling pathways
  • Antibody-driven pathology

The sponsor’s interest in immunology is evident in its focus on therapeutics intended for disorders where immune dysfunction contributes directly to disease burden.

Clinical Development in Rare Disease

The sponsor supports clinical investigation in a specialized rare disease setting, with research concentrated in a single active therapeutic area and coordinated across multiple collaborating sites in Canada.

  • Specialty disease research
  • Multisite clinical collaboration
  • Targeted therapeutic evaluation

Its research portfolio is centered on a focused clinical program in North America addressing an unmet need in specialty immunology.

Sponsored Trials

Trial Name Country Status
A Randomized, Double-Blind, Placebo-Controlled Study of AUR200 in Generalized Myasthenia GravisPoland PolandRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 2 total (50% not shared with other sponsors)

This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 10 sites collaborated multiple times

This sponsor has worked with 10 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Immune System Diseases1 trial
    322 other sponsors

Partnered Research Centres

10 centres
location_city
assignment77
Aidport Sp. z o.o.
Address
Ul Ksiedza Stanisława Kozierowskiego 24, 60-185 Poznan
Learn morearrow_forward
location_city
assignment16
CENTRUM MEDYCZNE HOPE CLINIC
Address
Nałęczowska 18/159, 20-701 Lublin
Learn morearrow_forward
location_city
assignment17
Clinirem Sp. z o.o.
Address
Ul. Polnocna 24/U1, 20-064 Lublin
Learn morearrow_forward
location_city
assignment4
MICS Centrum Medyczne Bydgoszcz
Address
ul. Jana Karola Chodkiewicz a 19C, 85-065 Bydgoszcz
Learn morearrow_forward
location_city
assignment8
Neurocor Banaszkiewicz Tomaszewski Lekarze sp.p.
Address
Ul. Mieczyslawa Medweckiego 7/u12, 31-870 Krakow
Learn morearrow_forward
location_city
assignment34
Neurologia Slaska Centrum Medyczne
Address
ul. Małachowskiego 51, 40-689 Katowice
Learn morearrow_forward
Page 1 of 2

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Aurinia Pharmaceuticals Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.